Question from Deputy Pádraig O'Sullivan - PQ 40640-26

To ask the Minister for Health the proportion of innovative oncology medicines approved at European level that are currently available and reimbursed in Ireland; the reason this proportion remains at approximately 25% given that the 180-day reimbursement timeline has been a legislative requirement under the Health Act 2013 for over a decade; the accountability measures that will be put in place to ensure the phased timeline under the new framework agreement is met at each stage; and if she will make a statement on the matter.